{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:23:37Z","timestamp":1792103017709,"version":"4.4.0"},"reference-count":36,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,2,12]]},"published-print":{"date-parts":[[2026,6]]},"DOI":"10.2967\/jnumed.125.271825","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:20:19Z","timestamp":1773930019000},"page":"936-942","source":"Crossref","is-referenced-by-count":6,"title":["Cost-Effectiveness Analysis of\n                    <sup>177<\/sup>\n                    Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective"],"prefix":"10.2967","volume":"67","author":[{"given":"Kemal C.","family":"Gogebakan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Kunst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Ghodsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Iravani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Etzioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"2026060105301019000_67.6.936.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026060105301019000_67.6.936.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00529-6"},{"key":"2026060105301019000_67.6.936.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2026060105301019000_67.6.936.4","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1007\/s00259-025-07317-9","article-title":"Cost-utility analysis of 177Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in Germany","volume":"52","author":"Brinkmann","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301019000_67.6.936.5","unstructured":"Ohm IK Kvist BCF Lidal IB . 177Lu-PSMA-617 for treatment of metastatic castration resistant prostate cancer: a health technology assessment 2023. https:\/\/www.fhi.no\/contentassets\/d1217cd2ddf045fab7a3febad0658010\/177lu-psma-617-for-treatment-of-metastatic-castration-resistant-prostate-cancer-hta-report-2023.pdf. Accessed May 10, 2025."},{"key":"2026060105301019000_67.6.936.6","unstructured":"Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments. Technology appraisal guidance no. TA930. National Institute for Health and Care Excellence website. https:\/\/www.nice.org.uk\/guidance\/ta930\/resources\/lutetium177-vipivotide-tetraxetan-for-treating-psmapositive-hormonerelapsed-metastatic-prostate-cancer-after-2-or-more-treatments-pdf-82615601351365. Published November 15, 2023. Accessed March 3, 2026."},{"key":"2026060105301019000_67.6.936.7","unstructured":"NICE Decision Support Unit. Partitioned survival analysis TSD. https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/partitioned-survival-analysis. Accessed May 17, 2025."},{"key":"2026060105301019000_67.6.936.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"2026060105301019000_67.6.936.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2026060105301019000_67.6.936.10","doi-asserted-by":"crossref","first-page":"i08","DOI":"10.18637\/jss.v070.i08","article-title":"Flexsurv: a platform for parametric survival modeling in R","volume":"70","author":"Jackson","year":"2016","journal-title":"J Stat Softw."},{"key":"2026060105301019000_67.6.936.11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2022.7070","article-title":"Cost-effectiveness analysis of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer","volume":"21","author":"Mehrens","year":"2023","journal-title":"J Natl Compr Canc Netw."},{"key":"2026060105301019000_67.6.936.12","unstructured":"Pan-Canadian oncology drug review initial economic guidance report: lutetium Lu 177 dotatate (Lutathera) for gastroenteropancreatic neuroendocrine tumors. Canadas Drug Agency website. https:\/\/www.cda-amc.ca\/sites\/default\/files\/pcodr\/Reviews2019\/10142LutetiumLu177dotatateGEP-NET_inEGR_NOREDACT-ABBREV_Post_31May2019_final.pdf. Published May 31, 2019. Accessed May 3, 2025."},{"key":"2026060105301019000_67.6.936.13","unstructured":"AMCP Guide To Pharmaceutical Payment Methods, 2013 Update (Version 3.0). Academy of Managed Care Pharmacy website. https:\/\/www.amcp.org\/sites\/default\/files\/2019-03\/Full-Pharmaceutical-Guide-%283.0%29.pdf. Accessed March 5, 2026."},{"key":"2026060105301019000_67.6.936.14","unstructured":"ASP pricing files. Centers for Medicare and Medicaid Services website. https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files. Accessed January 15, 2025."},{"key":"2026060105301019000_67.6.936.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06332-y"},{"key":"2026060105301019000_67.6.936.16","first-page":"92","article-title":"Hospice or hospital: the costs of dying of cancer in the oncology care model","volume":"1","author":"Hoverman","year":"2020","journal-title":"Palliat Med Rep."},{"key":"2026060105301019000_67.6.936.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"2026060105301019000_67.6.936.18","first-page":"204","article-title":"Estimating the costs of therapy in patients with relapsed and\/or refractory multiple myeloma: a model framework","volume":"8","author":"Roy","year":"2015","journal-title":"Am Health Drug Benefits."},{"key":"2026060105301019000_67.6.936.19","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1080\/13696998.2019.1661581","article-title":"Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance","volume":"22","author":"Barqawi","year":"2019","journal-title":"J Med Econ."},{"key":"2026060105301019000_67.6.936.20","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa223"},{"key":"2026060105301019000_67.6.936.21","unstructured":"Medicare Physician Fee Schedule 2016. Centers for Medicare and Medicaid Services website. https:\/\/www.cms.gov\/medicare\/medicare-fee-for-service-payment\/physicianfeesched\/pfs-relative-value-files-items\/rvu16a. Accessed May 1, 2025."},{"key":"2026060105301019000_67.6.936.22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196007"},{"key":"2026060105301019000_67.6.936.23","unstructured":"Consumer price index. U.S. Bureau of Labor Statistics website. https:\/\/www.bls.gov\/cpi\/factsheets\/medical-care.htm. Accessed May 10, 2025."},{"key":"2026060105301019000_67.6.936.24","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s11136-019-02117-9","article-title":"Estimating utilities\/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events","volume":"28","author":"Hall","year":"2019","journal-title":"Qual Life Res."},{"key":"2026060105301019000_67.6.936.25","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0580-7"},{"key":"2026060105301019000_67.6.936.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012360"},{"key":"2026060105301019000_67.6.936.27","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-013-0050-9"},{"key":"2026060105301019000_67.6.936.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2011.03.020"},{"key":"2026060105301019000_67.6.936.29","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-6-84"},{"key":"2026060105301019000_67.6.936.30","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12962-023-00472-6","article-title":"Cost-effectiveness thresholds or decision-making threshold: a novel perspective","volume":"21","author":"Sun","year":"2023","journal-title":"Cost Eff Resour Alloc."},{"key":"2026060105301019000_67.6.936.31","doi-asserted-by":"crossref","first-page":"105319","DOI":"10.1016\/j.healthpol.2025.105319","article-title":"Growth and changing landscape of the cost-utility literature: an Australian perspective, 19922022","volume":"156","author":"Xia","year":"2025","journal-title":"Health Policy."},{"key":"2026060105301019000_67.6.936.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00725-8"},{"key":"2026060105301019000_67.6.936.33","doi-asserted-by":"crossref","first-page":"S1742","DOI":"10.1016\/j.annonc.2025.09.101","article-title":"LBA6 Phase III trial of [177Lu] Lu-PSMA-617 combined with ADT+ ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)","volume":"36","author":"Tagawa","year":"2025","journal-title":"Ann Oncol."},{"key":"2026060105301019000_67.6.936.34","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu] Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026060105301019000_67.6.936.35","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet."},{"key":"2026060105301019000_67.6.936.36","unstructured":"Syed S . Access to Lu177-PSMA for prostate cancer: from clinical trials to the real world. https:\/\/dailynews.ascopubs.org\/do\/access-lu177-psma-prostate-cancer-clinical-trials-real-world Published October 1, 2025. Accessed November 1, 2025."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.271825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:18:27Z","timestamp":1785269907000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.271825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,1]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.2967\/jnumed.125.271825"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.271825","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]}}}